Allogeneic Stem Cell Therapy for Acute Ischemic Stroke

医学 改良兰金量表 冲程(发动机) 内科学 安慰剂 临床试验 中风恢复 物理疗法 缺血 缺血性中风 病理 康复 机械工程 替代医学 工程类
作者
Kiyohiro Houkin,Toshiya Osanai,Shinichiro Uchiyama,Kazuo Minematsu,Akihiko Taguchi,Katsuhiko Maruichi,Yoshimasa Niiya,Katsuyuki Asaoka,Yoshihiro Kuga,Katsumi Takizawa,Koichi Haraguchi,Shinichi Yoshimura,Kazumi Kimura,Koji Tokunaga,Atsuo Aoyama,Fusao Ikawa,Chikanori Inenaga,Tatsuya Abé,Atsushi Tominaga,Shinichi Takahashi
出处
期刊:JAMA Neurology [American Medical Association]
被引量:18
标识
DOI:10.1001/jamaneurol.2023.5200
摘要

Importance Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow–derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke. Objective To assess the efficacy and safety of MultiStem when administered within 18 to 36 hours of ischemic stroke onset. Design, Setting, and Participants The Treatment Evaluation of Acute Stroke Using Regenerative Cells (TREASURE) multicenter, double-blind, parallel-group, placebo-controlled phase 2/3 randomized clinical trial was conducted at 44 academic and clinical centers in Japan between November 15, 2017, and March 29, 2022. Inclusion criteria were age 20 years or older, presence of acute ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 8-20 at baseline), confirmed acute infarction involving the cerebral cortex and measuring more than 2 cm on the major axis (determined with diffusion-weighted magnetic resonance imaging), and a modified Rankin Scale (mRS) score of 0 or 1 before stroke onset. Data analysis was performed between May 9 and August 15, 2022. Exposure Patients were randomly assigned to either intravenous MultiStem in 1 single unit of 1.2 billion cells or intravenous placebo within 18 to 36 hours of ischemic stroke onset. Main Outcomes and Measures The primary end points were safety and excellent outcome at day 90, measured as a composite of a modified Rankin Scale (mRS) score of 1 or less, a NIHSS score of 1 or less, and a Barthel index score of 95 or greater. The secondary end points were excellent outcome at day 365, mRS score distribution at days 90 and 365, and mRS score of 0 to 1 and 0 to 2 at day 90. Statistical analysis of efficacy was performed using the Cochran-Mantel-Haenszel test. Results This study included 206 patients (104 received MultiStem and 102 received placebo). Their mean age was 76.5 (range, 35-95) years, and more than half of patients were men (112 [54.4%]). There were no between-group differences in primary and secondary end points. The proportion of excellent outcomes at day 90 did not differ significantly between the MultiStem and placebo groups (12 [11.5%] vs 10 [9.8%], P = .90; adjusted risk difference, 0.5% [95% CI, −7.3% to 8.3%]). The frequency of adverse events was similar between treatment groups. Conclusions and Relevance In this randomized clinical trial, intravenous administration of allogeneic cell therapy within 18 to 36 hours of ischemic stroke onset was safe but did not improve short-term outcomes. Further research is needed to determine whether MultiStem therapy for ischemic stroke has a beneficial effect in patients who meet specific criteria, as indicated by the exploratory analyses in this study. Trial Registration ClinicalTrials.gov Identifier: NCT02961504
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
雅哈完成签到,获得积分10
刚刚
1秒前
2秒前
3秒前
4秒前
安澜发布了新的文献求助10
4秒前
王佳亮发布了新的文献求助10
5秒前
5秒前
我不吃胡萝卜完成签到,获得积分10
8秒前
赘婿应助Huang_being采纳,获得10
8秒前
颜云尔发布了新的文献求助10
9秒前
凌辰发布了新的文献求助10
9秒前
11秒前
丹丹发布了新的文献求助10
12秒前
天天快乐应助Melody采纳,获得10
12秒前
Jasper应助正直凌文采纳,获得10
12秒前
坚强枫发布了新的文献求助10
13秒前
量子星尘发布了新的文献求助10
13秒前
14秒前
林林完成签到 ,获得积分10
15秒前
hhhh发布了新的文献求助30
16秒前
17秒前
壮观采文完成签到,获得积分10
19秒前
KIORking发布了新的文献求助10
20秒前
21秒前
张建发布了新的文献求助10
22秒前
Hello应助丹丹采纳,获得10
22秒前
28秒前
KIORking完成签到,获得积分10
29秒前
29秒前
安澜完成签到,获得积分20
29秒前
dsfsd发布了新的文献求助10
30秒前
30秒前
32秒前
32秒前
张涛发布了新的文献求助10
33秒前
酷波er应助Lee采纳,获得10
35秒前
呆瓜完成签到,获得积分10
37秒前
38秒前
小马的可爱老婆2完成签到,获得积分10
38秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988975
求助须知:如何正确求助?哪些是违规求助? 3531316
关于积分的说明 11253424
捐赠科研通 3269917
什么是DOI,文献DOI怎么找? 1804830
邀请新用户注册赠送积分活动 882063
科研通“疑难数据库(出版商)”最低求助积分说明 809068